

Prof. ABDULLAH MÜNÇİ YAĞCI

Personal Information

Office Phone: [+90 202](tel:+90202) Extension: 5579

Email: ayagci@gazi.edu.tr

Web: <https://avesis.gazi.edu.tr/ayagci>

International Researcher IDs

ORCID: 0000-0002-0458-2920

Yoksis Researcher ID: 2750

Education Information

Post Doctorate of Medicine, Gazi University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1999 - 2001

Undergraduate, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1982 - 1987

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Gazi University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2010 - Continues

Advising Theses

YAĞCI A. M., Hematolojik malignitesi olan hastalarda hepatit B virüsünün davranışı, Expertise In Medicine, H.TURGUT(Student), 2019

YAĞCI A. M., Research of calreticulin and JAK2 mutation in patients with essential thrombocytosis and primary myelofibrosis, Expertise In Medicine, S.ÜNAL(Student), 2016

YAĞCI A. M., Mültipl myelomlu hastalarda ilk sıra tedavinin ikinci küründen sonra değerlendirilen serbest hafif zincir oranlarının tedavi sonuçlarına etkisi, Expertise In Medicine, M.FATİH(Student), 2013

Jury Memberships

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Gazi Üniversitesi, October, 2023

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Gazi Üniversitesi, December, 2022

Appointment to Academic Staff - Associate Professorship, Appointment to Academic Staff - Associate Professorship, Gazi Üniversitesi, March, 2022

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic value of hyperlactatemia and lactate clearance in septic patients with hematological malignancies**
İNÇİ K., AYGENCEL BIKMAZ Ş. G., Gökçe O., TÜRKÖĞLU M., Kaynar L. A., Can F., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
ANNALS OF HEMATOLOGY, vol.103, no.10, pp.4239-4245, 2024 (SCI-Expanded)
- II. **Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL**
Chatzikonstantinou T., Scarfo L., Minga E., Karakatsoulis G., Chamou D., Kotaskova J., Iacoboni G., Demosthenous C., Albi E., Alcoceba M., et al.
HEMASPHERE, vol.8, no.9, 2024 (SCI-Expanded)
- III. **Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment**
Oriol A., Dimopoulos M., Schjesvold F., Beksac M., Facon T., Dhanasiri S., Guo S., Mu Y., Hong K., Gentili C., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.24, no.3, pp.165-0, 2024 (SCI-Expanded)
- IV. **Transcriptome Analysis of Beta-Catenin-Related Genes in CD34+ Haematopoietic Stem and Progenitor Cells from Patients with AML**
GÜNEŞ A., ÖZKAN T., Gurel K. A., Dalkilic S., BELDER N., Ozkeserli Z., ÖZDAĞ SEVGİLİ H., Beksac M., SAYINALP N., YAĞCI A. M., et al.
Mediterranean Journal of Hematology and Infectious Diseases, vol.16, no.1, 2024 (SCI-Expanded)
- V. **Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY**
Chatzikonstantinou T., Scarfo L., Karakatsoulis G., Minga E., Chamou D., Iacoboni G., Kotaskova J., Demosthenous C., Smolej L., Mulligan S., et al.
ECLINICALMEDICINE, vol.65, 2023 (SCI-Expanded)
- VI. **Risk factors for ICU mortality in patients with hematological malignancies: a single-center, retrospective cohort study from Turkey**
AYGENCEL BIKMAZ Ş. G., Gökçe O., Haşimoğlu M., BOYACI DÜNDAR N., TÜRKÖĞLU M., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
Turkish Journal of Medical Sciences, vol.53, no.1, pp.340-351, 2023 (SCI-Expanded)
- VII. **Occurrence of familial Mediterranean fever in haemophilia patients**
Kirkiz S., KAYA Z., GÖNEN S., YAĞCI A. M., KOÇAK Ü.
HAEMOPHILIA, vol.29, no.1, pp.165-171, 2023 (SCI-Expanded)
- VIII. **Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics**
Richardson P. G., Schjesvold F., Weisel K., Moreau P., Anderson L. D., White D., Rodriguez-Otero P., Sonneveld P., Engelhardt M., Jenner M., et al.
EUROPEAN JOURNAL OF HAEMATOLOGY, vol.108, no.1, pp.73-83, 2022 (SCI-Expanded)
- IX. **Infections in hematopoietic stem cell transplant patients admitted to Hematology intensive care unit: a single-center study.**
Barlas T., İnci K., AYGENCEL BIKMAZ Ş. G., TÜRKÖĞLU M., GÜZEL TUNÇCAN Ö., Can F., AYDIN KAYNAR L., ÖZKURT Z. N., YEGİN Z. A., Yagci M.
Hematology (Amsterdam, Netherlands), vol.26, no.1, pp.328-339, 2021 (SCI-Expanded)
- X. **Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines**
GÖKÇEN S., BAĞRIAÇIK E. Ü., KAYHAN H., Yağcı M.
LEUKEMIA RESEARCH, vol.110, 2021 (SCI-Expanded)
- XI. **Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis**
Spicka I., Moreau P., Martin T., Facon T., Martinez G., Oriol A., Koh Y., Lim A., Mikala G., Rosinol L., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, 2021 (SCI-Expanded)
- XII. **Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly**

Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis

Facon T, Moreau P, Martin T. G., Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosinol L, Yagci M, et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, 2021 (SCI-Expanded)

- XIII. **Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation**
YEGİN Z. A., ÖZKURT Z. N., DİKYAR A., AYDIN KAYNAR L., KARACAOĞLU YURDAGÜL Ö., Yagci M.
TRANSPLANTATION PROCEEDINGS, vol.53, no.6, pp.2013-2020, 2021 (SCI-Expanded)
- XIV. **Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma**
PAYDAŞ S., Lacin S., Dogan M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., Karadurmus N., Civriz S., Kaplan M. A., Yagci M., et al.
LEUKEMIA RESEARCH, vol.107, 2021 (SCI-Expanded)
- XV. **Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.**
Spicka I, Moreau P, Martin T. G., Facon T, Martinez G., Oriol A, Koh Y, Lim A, Mikala G, Rosinol L, et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XVI. **Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.**
Facon T, Moreau P, Martin T. G., Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosinol L, Yagci M, et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XVII. **IPS-3 Validation in 1012 cases with classical hodgkin lymphoma**
PAYDAŞ S., Lacin S., Dogan M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., Karadurmus N., Civriz S., Kaplan M. A., Yagci M., et al.
LEUKEMIA RESEARCH, vol.102, 2021 (SCI-Expanded)
- XVIII. **Can treating critically-ill haematological malignancy patients in a separate intensive care unit decrease intensive care unit mortality?**
AYGENCEL BIKMAZ Ş. G., BOYACI DÜNDAR N., TÜRKOĞLU M., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.4, pp.2095-2100, 2021 (SCI-Expanded)
- XIX. **Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma**
BEKSAÇ M., Aydin Y., GÖKER H., Turgut M., Besisik S. K., Cagirgan S., Tuglular T., VURAL F., Yagci M., ALACACIOĞLU İ., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, no.8, 2020 (SCI-Expanded)
- XX. **Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma**
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate A. S., VURAL F., Cascavilla N, Basu S, Johnson P, et al.
LEUKEMIA & LYMPHOMA, vol.61, no.8, pp.1850-1859, 2020 (SCI-Expanded)
- XXI. **A Randomized Study Comparing the Efficacy of Three Hepatitis B Vaccine Induction Regimens in Adult Patients with Hematological Malignancies**
ÖZKURT Z. N., Suyani E., Haznedar R., Yagci M.
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.3, pp.231-235, 2016 (SCI-Expanded)

Articles Published in Other Journals

- I. **Effects of COVID-19 Infection on Patients with Hematological Malignancy**
KAYNAR L. A., GÜZEL F. Ö., Dikyar A., Bostankolu Değirmenci B., BOZDAYI G., ERBAŞ G., KÖKTÜRK N., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.7, no.1, pp.14-19, 2023 (Peer-Reviewed Journal)

- II. **COVID-19 Enfeksiyonunun Hematolojik Maligniteli Hastalar Üzerine Etkiler**
AYDIN KAYNAR L., GÜZEL TUNÇCAN Ö., DİKYAR A., BOSTANKOLU DEĞİRMENCİ B., BOZDAYI G., ERBAŞ G., KÖKTÜRK N., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.7, no.1, pp.14-19, 2023 (Peer-Reviewed Journal)
- III. **Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis.**
Karadağ F. K., Yenerel M. N., Yılmaz M., Uskudar H., Ozkocaman V., Tuğlular T. F., Erdem F., Unal A., Ayyıldız O., Ozet G., et al.
American journal of blood research, vol.11, no.3, pp.279-285, 2021 (ESCI)
- IV. **Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysis**
KEKLİK KARADAĞ F., Yenerel M. N., YILMAZ M., ÜSKÜDAR TEKE H., ÖZKOCAMAN V., Tuğlular T. F., ERDEM F., ÜNAL A., Ayyıldız O., Ozet G., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.11, no.3, pp.279-285, 2021 (ESCI)
- V. **Acute pancreatitis complicating treatment of granulocytic sarcoma; cytosine arabinoside induced? A case report**
Ceneli O., Sucak G. T., YAĞCI A. M., KARAKAN T., Isik S., HAZNEDAR R.
HAEMA, vol.8, no.2, pp.297-300, 2005 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

- I. **Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).**
Hardin C., Gray C., Novelli S., Hacibekiroglu T., Yagci M., Birhiray R. E., Risal A., Namuduri M., Cai J., Ufkin M., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024
- II. **Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1).**
Birhiray R. E., Luminari S., Kim T. M., Yagci M., Wassenaar T. R., Risal A., Namuduri M., Cai J., Fearon-Chalet B., Zhu M., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024
- III. **Effects Of Radiofrequency Radiation And Magnetic Nanoparticles On Proliferation And Apoptosis Of Human Chronic Lymphocytic Leukemia Cell Line**
Gökçen S., Kayhan H., Taspınar E., Özgür Büyükcatalay E., Yağcı A. M.
The 4th Immuno-Oncology World Congress, Frankfurt, Germany, 4 - 05 December 2023, pp.20
- IV. **EVALUATION OF COVID-19 VACCINE ANTIBODY RESPONSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: USING RUXOLUTINIB OR IBRUTINIB NEGATIVELY EFFECTS VACCINE ANTIBODY RESPONSES**
SAVAŞ E. M., YILDIZ Ş., ÖZKURT Z. N., BALTAÇI Z., GÜZEL TUNÇCAN Ö., YEGİN Z. A., ÇAĞLAR K., KÖKTÜRK N., ERBAŞ G., BOZDAYI G., et al.
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.399-400
- V. **DOES THE CONSOLIDATION TREATMENT EFFICIENT AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS? WHICH REGIMEN IS FEASIBLE?**
ÖZKURT Z. N., YILDIZ Ş., DEMİREZEN A., YEGİN Z. A., YAĞCI A. M.
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.484-485
- VI. **Using severity and organ failure scores as prognostic factors in critically ill hematology patients**
Akcan E., Aygencel Bıkmaz Ş. G., Boyacı Dünder N., Türkoğlu M., Yegin Z. A., Özkurt Z. N., Yağcı A. M.
16th World Intensive and Critical Care Congress (WICC), İstanbul, Turkey, 26 - 30 August 2023, pp.100

- VII. **Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study**
Yağcı A. M.
ASH, Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.228-230
- VIII. **Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty**
Yağcı A. M.
asco, Illinois, United States Of America, 3 - 07 June 2022, vol.40, no.8024, pp.448
- IX. **Dihidroartemisinin'in İnsan Kronik Lenfositik Lösemi Hücre Serilerinde Apoptoza Etkilerinin İmmünomoleküler Değerlendirilmesi**
Gökçen S., Bağrıaçık E. Ü., Kayhan H., Yağcı A. M.
8. Ulusal Transplantasyon İmmünolojisi ve Genetiği Kongresi, Antalya, Turkey, 14 - 17 April 2022, pp.33
- X. **ALFA-1,4-Glukanın, Hct116 P53 Kolon Kanseri Hücre Serilerinde Apoptotik ve Proliferatif Etkilerinin Araştırılması**
Kayhan H., Gökçen S., Yağcı A. M.
8. Ulusal Transplantasyon İmmünolojisi ve Genetiği Kongresi, Antalya, Turkey, 14 - 17 April 2022, pp.15
- XI. **Miyelodisplastik Sendroma Sekonder Rekürren İnme Olgu Sunumu**
ERDOĞAN T., BATUR ÇAĞLAYAN H. Z., AKYÜREK N., YAĞCI A. M., NAZLIEL B.
57. Ulusal Nöroloji Kongresi, Antalya, Turkey, 27 November 2021
- XII. **Gebelik ve Covid 19 ile tetiklenen TTP : Olgu Sunumu**
AYDIN KAYNAR L., DİKYAR A., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
Hematoloji Uzmanlık Derneği Ulusal Kongresi, Turkey, 12 - 15 December 2020
- XIII. **Covid-19 enfeksiyonunun hematolojik maligniteli hastalar üzerine etkileri**
AYDIN KAYNAR L., GÜZEL TUNÇCAN Ö., DİKYAR A., BOSTANKOLU DEĞİRMENCİ B., YEGİN Z. A., ÖZKURT Z. N., YAĞCI A. M.
46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020
- XIV. **Can Bone Marrow Cells Be Differentiated and Counted Using a Novel Hematology Analyzer?**
KAYA Z., ÖZKURT Z. N., YAĞCI A. M., KOÇAK Ü.
ISTH 2020, Venedik, Italy, 12 July 2020
- XV. **Erişkin hemofili hastalarımızın analizi:Tek merkez deneyimi**
AYDIN KAYNAR L., ÖZKURT Z. N., YEGİN Z. A., DİKYAR A., YAĞCI A. M.
Hemofili vakalarla eğitim sempozyumu, Turkey, 21 - 23 February 2020
- XVI. **"Infections in Hematopoietic Stem Cell Transplantation Patients Admitted to Hematology Intensive Care Unit in Gazi University Hospital"**
BARLAS T., AYGENCEL BIKMAZ Ş. G., TÜRKOĞLU M., CAN F., AYDIN KAYNAR L., ÖZKURT Z. N., YEGİN Z. A., YAĞCI A. M.
16. Ulusal Dahili ve Cerrahi Bilimler Yoğun Bakım Kongresi, 8. Avrasya Yoğun Bakım Toplantısı, ANTALYA, 13 - 16 November 2019, vol.10, pp.66-67
- XVII. **"Evaluation of Colistin-induced nephrotoxicity in critically-ill haematology patients"**
AYGENCEL BIKMAZ Ş. G., TÜRKOĞLU M., CAN F., AYDIN KAYNAR L., ÖZKURT Z. N., YEGİN Z. A., YAĞCI A. M.
16. Ulusal Dahili ve Cerrahi Bilimler Yoğun Bakım Kongresi, 8. Avrasya Yoğun Bakım Toplantısı, ANTALYA, 13 - 16 November 2019, vol.10, pp.47-48
- XVIII. **Relaps ve Refrakter Hodgkin Lenfomada Brentuximab Vedotin Uzun Dönem Sonuçları: Çok Merkezli Gerçek Yaşam Deneyimi**
ÖZBALAK M. M., Salihoğlu A., SOYSAL T., Karadogan İ., PAYDAŞ S., Özdemir E., Yıldız B., KARADURMUŞ N., KAYNAR L., YAĞCI A. M., et al.
45. Ulusal Hematoloji Kongresi, Turkey, 30 October - 02 November 2019
- XIX. **HG3 hücre serisinde Dihidroartemisinin'xxin programlı hücre ölümü üzerine etkisi**
GÖKÇEN S., KAYHAN H., YAR SAĞLAM A. S., YAĞCI A. M.
16. Tıbbi Biyoloji ve Genetik Kongresi, 27 - 30 October 2019

- XX. **KLL HASTALARINDA PARANEOPLASTİK PEMFİGUS : OLGU SUNUMU**
AYDIN KAYNAR L., ÖZKURT Z. N., YEGİN Z. A., BAŞER DİKYAR A., AKYÜREK N., YAĞCI A. M.
ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019
- XXI. **KRONİK MYELOİD LÖSEMİLİ HASTALARDA İMATİNİBTEDAVİSİNİN RİSK SKORU VE DERİN MOLEKÜLER YANITSÜRELERİNE GÖRE KESİLMESİ**
YILMAZ S., DİKYAR A., yıldız a., CAN F., AYDIN KAYNAR L., albayrak m., KARAKUŞ S., ÇENELİ Ö., YAĞCI A. M.
ulusal hematoloji kongresi, Turkey, 30 October - 02 November 2019
- XXII. **evaluation of patients with PNH treated by eculizimab : real world data from Turkey**
AYDIN KAYNAR L., YAĞCI A. M.
61st Annual Meeting and Exposition (December 7-10, 2019), 7 - 10 December 2019
- XXIII. **Long-term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-center Real-life Experience**
FERHANOĞLU A. B., ÖZBALAK M. M., Salihoğlu A., SOYSAL T., Karadogan İ., PAYDAŞ S., Özdemir E., Yıldız B., KARADURMUŞ N., KAYNAR L., et al.
6th Aegean Hematology Oncology Symposium, 3 - 06 October 2019
- XXIV. **Adverse prognostic impact of pre-transplant neutrophil/lymphocyte ratio in lymphoproliferative disorders**
DİKYAR A., YEGİN Z. A., Can F., Yazici G., ÖZKURT Z. N., Ocal R., Yagci M.
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.465-466
- XXV. **Second autologous hematopoietic stem cell transplant versus chemoimmunotherapy in relapsed multiple myeloma after first transplantation: Single center data**
Can F., Ocal R., Kaynar L., YEGİN Z. A., Yagci M., Haznedar R., ÖZKURT Z. N.
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.502-503
- XXVI. **The impact of Pre-Transplant Cell-Free DNA levels on leukemia relapse and transplant related complications in allogeneic hematopoietic stem cell transplant recipients**
YEGİN Z. A., CAN F., GÖKÇEN S., EREN SADIOĞLU R., ÖZKURT Z. N., İLHAN Ç., YAĞCI A. M.
24th Congress of the European Hematology Association, Amsterdam, Netherlands, 13 - 16 June 2019
- XXVII. **THE IMPACT OF PRE-TRANSPLANT CELL-FREE DNA LEVELS ON LEUKEMIA RELAPSE AND TRANSPLANT RELATED COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**
YEGİN Z. A., CAN F., GÖKÇEN S., SADIOĞLU R. E., ÖZKURT Z. N., İLHAN Ç., YAĞCI A. M.
24th European Hematology Association (EHA) Congress, Amsterdam, Netherlands, 13 - 16 June 2019
- XXVIII. **COMPARISON OF CONSOLIDATION STRATEGIES IN ACUTE MYELOID LEUKEMIA: STANDARD CHEMOTHERAPY VS AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**
Dikyar A. A., Yeğın Z. A., CAN F., Kaynar L. A., ÖZKURT Z. N., YAĞCI A. M.
7th International Congress on Leukemia Lymphoma Myeloma - 2019, İstanbul, Turkey, 3 - 05 May 2019, vol.1, pp.38-39
- XXIX. **EFFICACY OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA**
CAN F., YEGİN Z. A., DİKYAR A., AYDIN KAYNAR L., ÖZKURT Z. N., YAĞCI A. M.
7th International Congress Leukemia Lymphoma Myeloma, 2 - 04 May 2019
- XXX. **hyperlactatemia, lactate clearance and outcome in critically ill patients with hematological malignancies**
İNCİ K., GÖKÇE O., TÜRKOĞLU M., YAĞCI A. M., ÖZKURT Z. N., AYDIN KAYNAR L., CAN F., AYGENCEL BIKMAZ Ş. G.
22nd international intensive care symposium, 1 - 02 May 2019
- XXXI. **Geçerli Kılma ve Doğrulama Parametreleriyle Kimerizm Analizi Çalışması**
KAYHAN H., GÖNEN S., YAĞCI A. M.
7. Ulusal Transplantasyon İmmünolojisi ve Genetiği Kongresi, Muğla, Turkey, 4 - 07 April 2019
- XXXII. **second autologous hematopoietic stem cell transplant versus chemoimmunotherapy in relapsed**

multiple myeloma after first transplattation : Single center data

CAN F., öcal r., AYDIN KAYNAR L., YEGİN Z. A., YAĞCI A. M., haznedar r., ÖZKURT Z. N.

EBMT 2019 45Th Annual Meeting -, 23 - 27 March 2019

XXXIII. ERİŞKİNDE ALL İDAME TEDAVİ YAN ETKİLERİ, YAN ETKİ YÖNETİMİ VE YAN ETKİLERİN SAĞ KALIM İLE İLİŞKİSİ

MERVE ECEM E. Y., ÖCAL R., GÖKÇEN S., YEĞİN Z. A., YAĞCI A. M., ÖZKURT Z. N.

44. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 31 October 2108 - 03 November 2018

XXXIV. Upper extremity aerobic exercise training improves exercise capacity in stem cell recipients

Bargi G., Guclu M., Özkurt Z. N., Yagci M.

28th International Congress of the European-Respiratory-Society (ERS), Paris, France, 15 - 19 September 2018, vol.52

XXXV. Determinants of physical inactivity in hematopoietic stem cells recipients

Bargi G., Guclu M., Özkurt Z. N., Yagci M.

28th International Congress of the European-Respiratory-Society (ERS), Paris, France, 15 - 19 September 2018, vol.52

XXXVI. Exercise capacity, muscle strength and quality of life in physical active and inactive hematopoietic stem cells recipients

Barđi G., Boşnak Güçlü M., Özkurt Z. N., Yağci A. M.

1st International Congress on Physiothernotherapy, Sarajevo, Bosnia And Herzegovina, 9 - 13 May 2018

XXXVII. Ig-A baskın diffüz proliferatif glomerülo nefrit tablosuyla ortaya çıkan anjiyoimmüno blastik T hücreli lenfoma olgusu

YILDIZ Ş., HELVACI Ö., KORUCU B., IŞIK GÖNÜL İ., AKYÜREK N., DERİCİ Ü., YAĞCI A. M.

Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi, Turkey, 9 - 13 May 2018

XXXVIII. Exercise capacity, muscle strength and quality of life in physical active and inactive hematopoietic stem cell recipients

bağrı g., güçlü m. b., ÖZKURT Z. N., YAĞCI A. M.

international Congress on Physiothernoyherapy, Bosnia And Herzegovina, 9 - 13 May 2018, pp.43

XXXIX. Hematopoetik Kök Hücre Nakli Alıcılarında Üst Ekstremitte Aerobik Egzersiz Eğitiminin Kardiyopulmoner Sonuç Ölçümleri Üzerine Etkileri

Barđi G., Boşnak Güçlü M., Özkurt Z. N., Yağci A. M.

Türk Toraks Derneđi 21. Yıllık Kongresi, Antalya, Turkey, 11 - 15 April 2018

XL. Effect of Different Treatment Patterns to Cost Effectiveness in Chronic Lymphocytic Leukemia Patients, Turkish CLL Study Group

DEMİRKAN F., VURAL F., TEKİNALP A., SEVİNDİK Ö. G., SAYINALP N., KAYNAR L., ERKURT M. A., HACIOĞLU S., YAĞCI A. M., TURGUT B.

American Society of Hematology, ATLANTA, United States Of America, 7 - 11 December 2017, vol.130, pp.5348

XLI. Hematopoetik Kök Hücre Nakli Alıcılarında Fiziksel Aktivite Seviyesi, Egzersiz Kapasitesi Ve Yaşam Kalitesi

BARĐI G., BOŞNAK GÜÇLÜ M., ÖZKURT Z. N., YAĞCI A. M.

43. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 04 November 2017

XLII. KRONİK MYELOSİTER LÖSEMİLİ HASTALARDA İMATİNİB TEDAVİSİNİN KESİLMESİ:ÇOK MERKEZLİ, İLERİYE DÖNÜK ÇALIŞMA 2.YIL SONUÇLARI

ÖZKURT Z. N., KARAKUŞ S., ÖCAL R., PEPELER M. S., GÖKÇEN S., YAĞCI A. M.

43. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 1 - 04 November 2017

XLIII. ATİPİK İMMUNFENOTİP ÖZELLİKLİ T HÜCRELİ BÜYÜK GRANÜLER LENFOSİTİK LÖSEMİ (T-LGL) OLGUSU

YILDIZ Ş., ÖCAL R., PEPELER M. S., YAĞCI A. M.

43. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 1 - 04 November 2017

XLIV. Esansiyel Trombositoz ve Primer Myelofibrozisli Hastalarda Kalretikülin Mutasyonu ve Kemik İliđi Fibrozisi İlişkisi

ÇAKMAK G., KAYHAN H., GÖKÇEN S., ÖZKURT Z. N., YEGİN Z. A., HAZNEDAR R., YAĞCI A. M.

43. Ulusal Hematoloji Kongresi, Turkey, 1 - 04 November 2017
- XLV. **Kronik Lenfositik Lösemi Patofizyolojisinde Nükleolin: Bir Apoptoz Belirteci Olabilir mi?**
YEGİN Z. A., Pepeler S., KAYHAN H., ÖZKURT Z. N., GÖKÇEN S., YAĞCI A. M.
43. Ulusal Hematoloji Kongresi, Turkey, 1 - 04 November 2017
- XLVI. **DAHA ÖNCE YOĞUN TEDAVİ ALMIŞ RELAPS/REFRAKTERMULTİPL MİYELOM HASTALARINDA DARATUMUMABİNTEKİLİLİK VE GÜVENLİLİĞİ**
BEKSAÇ M., aydın y., GÖKER H., TURGUT M., kalayoğlu beşişik s., çağırğan s., TUĞLULAR A. T., VURAL F., YAĞCI A. M., ALACACIOĞLU İ., et al.
43. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 1 - 04 November 2017
- XLVII. **Apoptotic effects of 2.1 GHz RF field exposure in human glioblastoma cell line**
TÜYSÜZ M. Z., KAYHAN H., YAR SAĞLAM A. S., YAĞCI A. M., BAĞRIAÇIK E. Ü., CANSEVEN KURŞUN A. G.
28-29. Ulusal Biyofizik Kongresi, 6 - 09 September 2017
- XLVIII. **İnsan Glioblastoma Hücre Hattında 2.1 GHz RF Alan Maruziyetinin Apoptotik Etkileri**
TÜYSÜZ M. Z., KAYHAN H., YAR SAĞLAM A. S., BAĞRIAÇIK E. Ü., YAĞCI A. M., CANSEVEN KURŞUN A. G.
28-29 Ulusal Biyofizik Kongresi, İstanbul, Turkey, 6 - 09 September 2017
- XLIX. **50 Hz frekansındaki ELF Alanların Meme Fibroblast Hücreleri Üzerine Etkisi**
EŞMEKAYA M. A., KAYHAN H., YAĞCI A. M., CANSEVEN KURŞUN A. G.
28-29. Ulusal Biyofizik Kongresi, Turkey, 6 - 09 September 2017
- L. **Ca2 electroporation in chronic-B lymphocytic leukaemia (MEC-1) cells**
COŞKUN A., EŞMEKAYA M. A., KAYHAN H., YAĞCI A. M., CANSEVEN KURŞUN A. G.
The 22nd Biomedical Science and Technology Symposium, 12 - 14 May 2017
- LI. **Kronik Myelositer Lösemili Hastalarda İmatinib Tedavisinin Kesilmesi Çok merkezli ileriye dönük bir çalışma**
YAĞCI A. M., ÖZKURT Z. N., GÖKÇEN S.
42 Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- LII. **Hematolojik maligniteli hastalar için ayrı bir yoğun bakım ünitesi gerekli midir**
BOYACI N., Güllü Z., ÖZKURT Z. N., YAĞCI A. M., TÜRKOĞLU M., AYGENCEL BIKMAZ Ş. G.
12. Ulusal Dahili ve Cerrahi Bilimler Yoğun Bakım Kongresi, 4. Avrasya Yoğun Bakım Toplantısı, Ankara, Turkey, 4 - 07 November 2015
- LIII. **Hematolojik maligniteli hastalarda yoğun bakım mortalitesine etkili faktörler**
BOYACI N., Güllü Z., ÖZKURT Z. N., YAĞCI A. M., TÜRKOĞLU M., AYGENCEL BIKMAZ Ş. G.
12. Ulusal Dahili ve Cerrahi Bilimler Yoğun Bakım Kongresi, 4. Avrasya Yoğun Bakım Toplantısı, Ankara, Turkey, 4 - 07 November 2015
- LIV. **Co occurrence of Graves disease and immune thrombocytopenia a case report**
YALÇIN M. M., ARSLAN İ. E., TÖRÜNER F. S., EROĞLU ALTINOVA A., AKTÜRK M. Y., DUMLUDAĞ B., YAĞCI A. M., YETKİN İ., ARSLAN M.
Avrupa Endokrinoloji Kongresi, 16 - 20 May 2015
- LV. **Mitochondrial Hyperpolarization and Cytochrome c Release in Microwave Exposed MCF 7 cells**
SEYHAN H. N., CANSEVEN KURŞUN A. G., EŞMEKAYA M. A., KAYHAN H., TÜYSÜZ M. Z., ARAL B., YAĞCI A. M.
BioEM2014, Joint Meeting of The Bioelectromagnetics Society and the European BioElectromagnetics Association, 8 - 13 June 2014
- LVI. **2 1 GHz Frekanslı W CDMA Modülasyonlu Mikrodalga Radyasyonun Meme Adenokarsinoma MCF 7 Hücrelerine Etkileri**
EŞMEKAYA M. A., KAYHAN H., TÜYSÜZ M. Z., CANSEVEN KURŞUN A. G., YAĞCI A. M., SEYHAN H. N.
II. Elektromanyetik Alanlar ve Etkileri Sempozyumu, Turkey, 8 - 09 November 2013
- LVII. **1 8 GHz Mikrodalga Radyasyonun Burkitt Lenfoma Raji Hücrelerinde Apoptotik Aktivite ve Bcl 2 Gen Ekspresyon düzeyine etkisi**
EŞMEKAYA M. A., KAYHAN H., ALP E., ÖNENÇ İ., TÜYSÜZ M. Z., CANSEVEN KURŞUN A. G., MENEVŞE E. S., YAĞCI A. M., SEYHAN H. N.
25. ULUSAL BİYOFİZİK KONGRESİ, Turkey, 24 - 27 September 2013
- LVIII. **KISA SÜRELİ MİKRODALGA MW RADYASYON MARUZİYETİNİN DERİ FİBROBLAST HÜCRELERİ HÜCRE**

CANLILIĞI VE APOPTOTİK DÜZEYLERİ ÜZERİNE ETKİSİ

EŞMEKAYA M. A., KAYHAN H., CANSEVEN KURŞUN A. G., YAĞCI A. M., SEYHAN H. N.

39. Ulusal Fizyoloji Kongresi, Turkey, 10 - 14 September 2013

LIX. **2.1 GHz Microwave Radiation Induces Apoptosis and m Depolarization in Human Breast Fibroblast Cells**

SEYHAN H. N., EŞMEKAYA M. A., KAYHAN H., TUYSUZ M. Z., CANSEVEN KURŞUN A. G., YAĞCI A. M.

Joint Meeting of The Bioelectromagnetics Society and the European BioElectromagnetics Association, 10 - 14 June 2013

LX. **UV B Radyasyon Uygulamasının İnsan Kan Lenfositlerinde Hucre Canlılığı Uzerindeki Etkisi**

CANSEVEN KURŞUN A. G., EŞMEKAYA M. A., GÖKÇEN S., YAĞCI A. M., SEYHAN H. N.

24. Ulusal Biyofizik Kongresi, Turkey, 25 - 28 September 2012

LXI. **Gemsitabin Demir III Klorür ve ELF Manyetik Alan Uygulamasının İnsan Lenfosit Hücreleri Apoptotik Aktiviteleri Üzerine Etkisi**

EŞMEKAYA M. A., KAYHAN H., CANSEVEN KURŞUN A. G., YAĞCI A. M., SEYHAN H. N.

Elektromanyetik Alanlar ve Etkileri Sempozyumu, Turkey, 7 - 08 October 2011

LXII. **Survivin expression correlates with Ki-67 in multiple myeloma.**

Haznedar R., Akyurek N., Akar I., Yagci M., Sucak G., Ataoglu O.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

Supported Projects

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, 2023 - 2030

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronektamab, an anti-CD20 × anti-CD3 bispecific antibody in Previously Untreated Participants with Follicular Lymphoma (FL) (OLYMPIA-2)), 2023 - 2029

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronektamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Follicular Lymphoma (FL) (OLYMPIA-1), 2023 - 2029

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronektamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3), 2023 - 2029

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, 2023 - 2029

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, 2022 - 2028

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation, 2021 - 2027

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, MOR208C310A Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma, 2022 - 2026

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Randomized, Open-Label, Phase 3 Trial of

Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma, 2021 - 2026

Yağcı A. M., Other International Funding Programs, A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤ 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma / D8227C00001 / ACE-LY-312, 2020 - 2025

GÖKÇEN S., KAYHAN H., YAĞCI A. M., ÖZKURT Z. N., YEGİN Z. A., Project Supported by Higher Education Institutions, Kronik Lenfositik Lösemi Hücrelerinde Dioscinin NLRP3 İnflamazomun İfadelemesine ve Apoptoza Etkileri, 2023 - 2024

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemo immunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, 2019 - 2024

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT), 2016 - 2024

Yağcı A. M., Industrial Organizations of Other Countries Supported Project, A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma, 2014 - 2024

Metrics

Publication: 182

Citation (WoS): 2121

Citation (Scopus): 2374

H-Index (WoS): 17

H-Index (Scopus): 18